Immunotherapy Research Labs

Show: 10 · 20 · 50

  1. 1
  2. 2
  • Bert Vogelstein Laboratory

    The Bert Vogelstein Laboratory seeks to develop new approaches to the prevention or treatment of cancers through a better understanding of the genes and pathways underlying their pathogenesis.

    Our major focus is on cancers of the colon and rectum. We have shown that each colon neoplasm arises fro...m a clonal expansion of one transformed cell. This expansion gives rise to a small benign colon tumor (called a polyp or adenoma). This clonal expansion and subsequent growth of the tumors appears to be caused by mutations in oncogenes and tumor suppressor genes, and the whole process is accelerated by defects in genes required for maintaining genetic instability. Mutations in four or five such genes are required for a malignant tumor to form, while fewer mutations suffice for benign tumorigenesis. As the mutations accumulate, the tumors become progressively more dangerous.

    Current studies are aimed at the further characterization of the mechanisms through which these genes act, the identification of other genes that play a role in this tumor type, and the application of this knowledge to patient management.
    view more

    Lab Website

    Principal Investigator

    Bert Vogelstein, M.D.

  • Cynthia Sears Laboratory

    Work in the Cynthia Sears Laboratory focuses on the bacterial contributions to the development of human colon cancer and the impact of the microbiome on other cancers and the therapy of cancer. The current work involves mouse and human studies to define how enterotoxigenic Bacteroides fragilis, pks+... Escherichia coli, Fusobacterium nucleatum, biofilms and the colonic microbiota induce chronic colonic inflammation and colon cancer. Prospective human studies of the microbiome and biofilms in screening colonoscopy are in progress as are studies to determine if and how the microbiome impacts the response of individuals with cancer to immunotherapy and other cancer therapies.

    view more

    Principal Investigator

    Cynthia Sears, M.D.

  • Drew Pardoll Lab

    The Pardoll Lab focuses on the regulation of antigen-specific T cell responses and studies approaches to modify these responses for immunotherapy. Pardoll has a particular interest in cancer immunology and his lab’s studies on basic immunologic mechanisms have led to the development and design of a ...number of cancer vaccines and discovery of key checkpoint ligands and receptors, such as PD-L2, LAG-3 and neuritin, many of which are being targeted clinically.

    Our primary pursuits are discovering and elucidating new molecules that regulate immune responses, investigating the biology of regulatory T cells, and better understanding the specific biochemical signatures that allow a patient’s T cells to selectively target cancer cells.
    view more

    Principal Investigator

    Drew Pardoll, M.D., Ph.D.

  • Drug Discovery Group

    Barbara Slusher, M.A.S., Ph.D., leads a 20-member veteran drug discovery team of medicinal chemists, assay developers, pharmacologists, toxicologists and pharmacokinetic/drug metabolism experts, who identify novel drug targets arising from JHU faculty’s research and translate them into new, small mo...lecule drug therapies.

    Her team collaborates extensively with faculty at the Bloomberg~Kimmel Institute for Cancer Immunotherapy and leads the BKI immunotherapy drug discovery core, aimed at developing new immune-targeting drug therapies for laboratory and clinical testing at Johns Hopkins.
    view more

  • Elisseeff Lab

    The mission of the Elisseeff Lab is to engineer technologies to repair lost tissues. We aim to bridge academic research and technology discovery to treat patients and address clinically relevant challenges related to tissue engineering. To accomplish this goal we are developing and enabling material...s, studying biomaterial structure-function relationships and investigating mechanisms of tissue development to practically rebuild tissues. The general approach of tissue engineering is to place cells on a biomaterial scaffold that is designed to provide the appropriate signals to promote tissue development and ultimately restore normal tissue function in vivo. Understanding mechanisms of cellular interactions (both cell-cell and cell-material) and tissue development on scaffolds is critical to advancement of the field, particularly in applications employing stem cells. Translation of technologies to tissue-specific sites and diseased environments is key to better design, understanding, and ultimately efficacy of tissue repair strategies. We desire to translate clinically practical strategies, in the form of biomaterials/medical devices, to guide and enhance the body's natural capacity for repair. To accomplish the interdisciplinary challenge of regenerative medicine research, we maintain a synergistic balance of basic and applied/translational research. view more

    Lab Website

    Principal Investigator

    Jennifer Elisseeff, Ph.D.

  • Elizabeth M. Jaffee, M.D.

    Current projects include:

    The evaluation of mechanisms of immune tolerance to cancer in mouse models of breast and pancreatic cancer. We have characterized the HER-2/neu transgenic mouse model of spontaneous mammary tumors.
    This model demonstrates immune tolerance to the HER-2/neu gene pro...duct. This model is being used to better understand the mechanisms of tolerance to tumor. In addition, this model is being used to develop vaccine strategies that can overcome this tolerance and induce immunity potent enough to prevent and treat naturally developing tumors. More recently, we are using a genetic model of pancreatic cancer developed to understand the early inflammatory changes that promote cancer development.

    The identification of human tumor antigens recognized by T cells. We are using a novel functional genetic approach developed in our laboratory. Human tumor specific T cells from vaccinated patients are used to identify immune relevant antigens that are chosen based on an initial genomic screen of overexpressed gene products. Several candidate targets have been identified and the prevelence of vaccine induced immunity has been assessed .
    This rapid screen to identify relevant antigenic targets will allow us to begin to dissect the mechanisms of tumor immunity induction and downregulation at the molecular level in cancer patients. More recently, we are using proteomics to identify proteins involved in pancreatic cancer development. We recently identified Annexin A2 as a molecule involved in metastases.

    The analysis of antitumor immune responses in patients enrolled on vaccine studies. The focus is on breast and pancreatic cancers. We are atttempting to identify in vitro correlates of in vivo antitumor immunity induced by vaccine strategies developed in the laboratory and currently under study in the clinics.
    view more

    Lab Website

    Principal Investigator

    Elizabeth Jaffee, M.D.

  • Fan Pan Lab

    The Fan Pan Lab uses molecular, biochemical and mouse genetic approaches to explore the molecular mechanisms controlling the development, lineage stability and function of T cell subsets. The team currently focuses on regulatory and effector T cells, which are important for immune control or immune ...activation. Research in the lab will help scientists better understand the mechanisms behind immune regulation and will aid in the development of new immunotherapies for the treatment of cancer and autoimmune diseases. view more

    Lab Website

    Principal Investigator

    Fan Pan, M.D., Ph.D.

  • Franck Housseau Lab

    The Franck Housseau Lab focuses on the role of the microbiome in colorectal tumorigenesis and on developing a better understanding of the tumor immune microenvironment. The lab is currently working to define the biomarkers of a pre-existing antitumor immune response in metastatic colorectal cancer t...o define a population of patients eligible for checkpoint blockade therapies. view more

    Principal Investigator

    Franck Housseau, Ph.D.

  • Ivan Borrello Lab

    The Ivan Borrello Lab focuses on the development of a novel approach of adoptive T cell therapy utilizing marrow-infiltrating lymphocytes (MILs) as a more tumor-specific T cell approach. This has led to establishing the first adoptive T cell trials at Johns Hopkins and an exploration of this approac...h in other diseases, including nonhematologic malignancies. The lab also examines strategies for treating minimal residual disease (MRD) in myeloma with the combination of immune modulation and whole cell-based vaccines. view more

    Lab Website

    Principal Investigator

    Ivan Borrello, M.D.

  • Jonathan D. Powell Lab

    The program in cancer and immunometabolism seeks to both understand and target metabolic programming in both the cancer and immune cells in order to enhance immunotherapy for cancer. To this end, in collaboration in with the Johns Hopkins Drug Discovery Program, the lab is developing novel agents t...hat target tumor glutamine metabolism. These compounds not only inhibit tumor growth but render tumors more susceptible to immunotherapies such as checkpoint blockade and adoptive cellular therapy. Additionally, the group is dissecting key metabolic pathways that regulate immune cell activation, differentiation and function. By targeting these pathways, they are discovering new ways to both enhance the efficacy of antitumor T cells as well as inhibit T regulatory cells and myeloid-derived suppressor cells. view more

  1. 1
  2. 2